Mepolizumab in severe asthma: Turkish real-world data from a bi-directional, self-controlled study
Bildiriler > Özet Bildiri
Yazarlar: Sevim Bavbek, Arzu Yorgancioglu, Fatma Merve Tepetam, Insu Yılmaz, Kurtulus Aksu, Özlem GÖKSEL, Canturk Tasci, Yavuz Havlucu, V. Dilsad Mungan, Ismet Bulut, Cagcan Olmez, Ezgi Demiralp, Gabriela Abreu, Juliana Queiroz, Saeed Noibi
Airway pharmacology and treatment, , , Uluslararası, Özet Bildiri, ss PA320-PA320
DOI: 10.1183/13993003.congress-2025.pa320
Özet
Background The multi-country Nucala Effectiveness Study (NEST) assessed mepolizumab (MEPO) effectiveness in patients with severe asthma with an eosinophilic phenotype (SAEP; Al-Lehebi, R.O. et al. Adv Ther 2024;41:4008–31). Aim Summarise data on clinically significant exacerbations (CSE) and oral corticosteroid (OCS) use in NEST Türkiye cohort. Methods This bi-directional study assessed 12 months pre- and post-MEPO initiation data. Primary endpoint: incidence rate ratio (IRR) of CSEs (asthma worsening requiring systemic corticosteroid use for ≥3 days and/or emergency room visit and/or hospital admission). Key secondary endpoint: change in maintenance OCS use. Results The cohort comprised 150 patients (mean age: 48 years; 76% female). MEPO exposure increased the number of patients with no CSEs (122 [81.9%]) versus pre-MEPO (36 [25.7%]). The proportion of patients with ≥1 CSE was lower post-MEPO (18.1%) than pre-MEPO (74.3%). The mean (95% confidence interval [CI]) number of CSEs/patient in pre- and post-MEPO periods was 2.9 (2.4–3.5) and 0.3 (0.2–0.4), respectively. CSEs reduced by 91% post-MEPO versus pre-MEPO (IRR [95%CI]: 0.09 [0.06–0.14]; p<0.001). Maintenance OCS use decreased from 125 (83.3%) patients pre-MEPO to 32 (21.3%) post-MEPO (Figure). Conclusions MEPO significantly reduced CSE frequency and OCS use in patients with SAEP supporting its clinical use in SAEP maintenance. erj;66/suppl_69/PA320/F1 F1 F1